113 related articles for article (PubMed ID: 11280437)
1. Liposomal bleomycin: increased therapeutic activity and decreased pulmonary toxicity in mice.
Arndt D; Zeisig R; Bechtel D; Fichtner I
Drug Deliv; 2001; 8(1):1-7. PubMed ID: 11280437
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of liposomal alpha-tocopherol against bleomycin-induced lung injury.
Suntres ZE; Shek PN
Biomed Environ Sci; 1997 Mar; 10(1):47-59. PubMed ID: 9099426
[TBL] [Abstract][Full Text] [Related]
3. Toxicity and antitumor activity of niosomal bleomycin in tumor bearing mice.
Naresh RA; Udupa N; Devi PU
Indian J Exp Biol; 1996 Aug; 34(8):764-72. PubMed ID: 8979482
[TBL] [Abstract][Full Text] [Related]
4. Relative pulmonary toxicity and antitumor effects of two new bleomycin analogs, pepleomycin and tallysomycin A.
Sikic BI; Siddik ZH; Gram TE
Cancer Treat Rep; 1980; 64(4-5):659-67. PubMed ID: 6159079
[TBL] [Abstract][Full Text] [Related]
5. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes.
Harasym TO; Cullis PR; Bally MB
Cancer Chemother Pharmacol; 1997; 40(4):309-17. PubMed ID: 9225948
[TBL] [Abstract][Full Text] [Related]
6. Improved therapeutic index of bleomycin when administered by continuous infusion in mice.
Sikic BI; Collins JM; Mimnaugh EG; Gram TE
Cancer Treat Rep; 1978 Dec; 62(12):2011-7. PubMed ID: 87269
[TBL] [Abstract][Full Text] [Related]
7. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol).
Parr MJ; Masin D; Cullis PR; Bally MB
J Pharmacol Exp Ther; 1997 Mar; 280(3):1319-27. PubMed ID: 9067319
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties.
Zou Y; Ling YH; Van NT; Priebe W; Perez-Soler R
Cancer Res; 1994 Mar; 54(6):1479-84. PubMed ID: 8137251
[TBL] [Abstract][Full Text] [Related]
9. Tallysomycin S10b: experimental antitumor activity and toxicity.
Schurig JE; Rose WC; Hirth RS; Schlein A; Huftalen JB; Florczyk AP; Bradner WT
Cancer Chemother Pharmacol; 1984; 13(3):164-70. PubMed ID: 6207948
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antitumor effect of targeted nanoliposomal bleomycin.
Chiani M; Azadmanesh K; Shokrgozar MA; Mehrabi MR; Akbarzadeh A; Norouzian D
Chem Biol Drug Des; 2017 Nov; 90(5):953-961. PubMed ID: 28498511
[TBL] [Abstract][Full Text] [Related]
11. Paradoxical effects of bleomycin and heavy water (D2O) in mice.
Gaeng DP; Geiser M; Cruz-Orive LM; Larsen SE; Schaffner T; Laissue JA; Altermatt HJ
Int J Cancer; 1995 Sep; 62(6):784-90. PubMed ID: 7558431
[TBL] [Abstract][Full Text] [Related]
12. Mouse models of bleomycin-induced pulmonary fibrosis.
Walters DM; Kleeberger SR
Curr Protoc Pharmacol; 2008 Mar; Chapter 5():Unit 5.46. PubMed ID: 22294226
[TBL] [Abstract][Full Text] [Related]
13. Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity.
Dos Santos N; Waterhouse D; Masin D; Tardi PG; Karlsson G; Edwards K; Bally MB
J Control Release; 2005 Jun; 105(1-2):89-105. PubMed ID: 15878792
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
Fujimoto K; Oka T; Morimoto M
Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
[TBL] [Abstract][Full Text] [Related]
15. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo.
Xiong XB; Huang Y; Lu WL; Zhang H; Zhang X; Zhang Q
Pharm Res; 2005 Jun; 22(6):933-9. PubMed ID: 15948037
[TBL] [Abstract][Full Text] [Related]
16. [Experimental study of the production and prevention of lung diseases observed during treatment with bleomycin].
Flandre O; Beaulaton IS; Damon M; Allieu M
Therapie; 1972; 27(1):67-76. PubMed ID: 4111716
[No Abstract] [Full Text] [Related]
17. Bleomycin induces strain-dependent alterations in the pattern of epithelial cell-specific marker expression in mouse lung.
Daly HE; Baecher-Allan CM; Barth RK; D'Angio CT; Finkelstein JN
Toxicol Appl Pharmacol; 1997 Feb; 142(2):303-10. PubMed ID: 9070353
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
Allen TM; Mumbengegwi DR; Charrois GJ
Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
[TBL] [Abstract][Full Text] [Related]
19. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
20. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
